ArticleBMC infectious diseases2025
Clinical features, epidemiology, treatment, and prognosis of multicentre pediatric pneumococcal meningitis in China from 2019 to 2021.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
Abstract
objectivePneumococcal meningitis (PM) causes significant illness and death in children worldwide, especially in high-burden countries. This multicenter study aimed to examine the epidemiology, clinical symptoms, prognosis, strain serotyping, antibiotic resistance, and outcome-related factors in children with PM.
methodsA prospective surveillance study on children under 18 years old with laboratory-confirmed invasive pneumococcal disease (IPD) was conducted at 19 hospitals, mainly in tertiary pediatric hospitals, from 2019 to 2021. This period was early in the post-PCV13 era in China, when the vaccine had been licensed but coverage was still limited. Given the high morbidity associated with PM, we collected data on children diagnosed with PM between January 1, 2019, and December 31, 2021. We thoroughly analyzed their demographics, epidemiology, vaccination status, clinical characteristics, laboratory results, treatment, and prognosis.
resultsA total of 157 children participated in this study, with a median age of 30.4 (9.7, 53.7) months. Only three children had received the vaccination before admission. The most common season of onset was winter (37.6%), with a bimodal peak of incidence occurring in January and April. Overall, 61 children (38.9%) had a poor prognosis at discharge, and 30 children (19.1%) died during the disease course or follow-up. Among the 157 patients, serotyping was successfully performed in 118 (75.2%) cases, identifying 25 distinct serotypes. Among the 118 serotyped isolates, the most dominant serotypes were 19F (26.3%), followed by 23F (12.7%) and 6B (11.9%). All strains were sensitive to vancomycin (100.0%) and levofloxacin (100.0%), followed by ceftriaxone (61.9%). Interestingly, serotype 19F was more likely to be resistant to penicillin, ceftriaxone, and trimethoprim-sulfamethoxazole compared with other serotypes, while serotypes 14 and 15A were more sensitive to trimethoprim-sulfamethoxazole than other serotypes. In addition, among the 118 serotyped isolates, 112 (94.9%) were classified as multidrug-resistant (MDR). Among these MDR isolates, 51.7% exhibited combined resistance to β-lactams, macrolides, clindamycin, tetracyclines, and trimethoprim-sulfamethoxazole.
conclusionsChildren with PM had a poor prognosis and a high mortality rate. Most children with PM were not vaccinated before admission. Nearly three-quarters of isolates were included in PCV13. Pneumococcal vaccination may still be effective in preventing PM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.